Paradigm Biopharmaceuticals Ltd (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$173.24 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
389.43 million
Earnings per share
-0.200
Dividend per share
N/A
Year To Date Return
18.67%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Ltd (ASX: PAR)
Latest News
Share Market News
Mesoblast shares halted as it asks investors to tip in another $75 million
Share Market News
US congressman resigns over ASX insider trading penny stock scandal
Share Market News
5 small-cap shares I'm watching in FY 2020
Share Gainers
Why Nufarm, Paradigm, ResApp, & Zip Co shares charged higher today
Share Market News
Paradigm reports "ground-breaking" osteoarthritis discovery: Is it the real deal?
Share Market News
Is Paradigm Biopharmaceuticals the share market's next huge winner?
Share Market News
Why the Bionomics share price is up 40% today
Share Market News
Paradigm share price tanks despite positive clinical trial update
Share Market News
Why the Mesoblast share price is going nuts today
Share Market News
Opthea share price lifts on clinical trial update: Is it a spec buy?
Share Gainers
Why Ausdrill, Link, Paradigm, & Village Roadshow shares raced higher today
Share Market News
Here's why the Opthea share price is up 130% today
Frequently Asked Questions
-
No, Paradigm does not pay shareholder dividends at this time.
-
Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Ltd
Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.
Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe.
PAR Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 09 Jan 2025 | $0.45 | $-0.03 | -6.38% | 3,259,818 | $0.47 | $0.47 | $0.44 |
| 08 Jan 2025 | $0.47 | $0.03 | 6.74% | 4,550,740 | $0.46 | $0.50 | $0.45 |
| 07 Jan 2025 | $0.45 | $0.05 | 12.50% | 3,542,756 | $0.40 | $0.45 | $0.39 |
| 06 Jan 2025 | $0.40 | $-0.01 | -2.44% | 1,792,912 | $0.42 | $0.43 | $0.39 |
| 03 Jan 2025 | $0.41 | $0.01 | 2.50% | 1,742,847 | $0.40 | $0.42 | $0.39 |
| 02 Jan 2025 | $0.40 | $0.03 | 8.00% | 2,040,867 | $0.38 | $0.42 | $0.38 |
| 31 Dec 2024 | $0.38 | $-0.01 | -2.63% | 848,594 | $0.39 | $0.39 | $0.37 |
| 30 Dec 2024 | $0.38 | $-0.01 | -2.56% | 2,647,362 | $0.40 | $0.40 | $0.38 |
| 27 Dec 2024 | $0.39 | $0.02 | 5.33% | 1,298,945 | $0.38 | $0.41 | $0.38 |
| 24 Dec 2024 | $0.38 | $-0.02 | -5.13% | 885,121 | $0.39 | $0.39 | $0.38 |
| 23 Dec 2024 | $0.39 | $0.02 | 5.33% | 2,189,069 | $0.39 | $0.41 | $0.39 |
| 20 Dec 2024 | $0.38 | $0.01 | 2.74% | 1,328,227 | $0.38 | $0.39 | $0.38 |
| 19 Dec 2024 | $0.37 | $-0.01 | -2.67% | 1,191,173 | $0.37 | $0.40 | $0.37 |
| 18 Dec 2024 | $0.38 | $0.00 | 0.00% | 1,900,115 | $0.37 | $0.40 | $0.37 |
| 17 Dec 2024 | $0.38 | $0.02 | 5.63% | 2,489,626 | $0.36 | $0.40 | $0.36 |
| 16 Dec 2024 | $0.36 | $-0.03 | -7.89% | 2,492,827 | $0.38 | $0.38 | $0.36 |
| 13 Dec 2024 | $0.38 | $-0.04 | -9.52% | 4,720,347 | $0.42 | $0.42 | $0.38 |
| 12 Dec 2024 | $0.42 | $-0.03 | -6.74% | 2,435,658 | $0.43 | $0.44 | $0.42 |
| 11 Dec 2024 | $0.45 | $-0.07 | -13.59% | 2,834,329 | $0.50 | $0.51 | $0.45 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 20 Dec 2024 | Paul Rennie | Buy | 1,700,000 | $637,500 |
Employee Share Ownership Plan. 1,700,000 - Performance Rights
|
| 03 Dec 2024 | Paul Rennie | Expiry | 349,500 | $173,002 |
Options expired.
|
| 03 Dec 2024 | Matthew Fry | Expiry | 1,302,372 | $644,674 |
Options expired.
|
| 22 Oct 2024 | Donna Skerrett | Expiry | 1,000,000 | $215,000 |
As advised by the company. lapsed
|
| 22 Oct 2024 | Paul Rennie | Expiry | 1,200,000 | $258,000 |
As advised by the company. Lapsed, 1,200,000 Performance Rights, as per announcement on 23-10-2024
|
| 15 Oct 2024 | Paul Rennie | Buy | 95,300 | $20,145 |
On-market trade.
|
| 14 Oct 2024 | Matthew Fry | Buy | 200,000 | $42,750 |
On-market trade.
|
| 10 Oct 2024 | Paul Rennie | Buy | 150,000 | $30,690 |
On-market trade.
|
| 10 Oct 2024 | Matthew Fry | Buy | 150,000 | $30,500 |
On-market trade.
|
| 29 Feb 2024 | Donna Skerrett | Issued | 1,000,000 | $350,000 |
As advised by the company. Employee Performance Rights Plan
|
| 29 Feb 2024 | Paul Rennie | Issued | 1,200,000 | $420,000 |
As advised by the company. Employee Performance Rights Plan, 1,200,000 Rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Paul Rennie | Executive DirectorManaging DirectorExecutive Chairman | May 2014 |
Mr Rennie has sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. Paul's experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager and Soltec (FH Faulding Ltd) as their Director of business development. Paul also led the commercialisation of Recaldent a novel biopharmaceutical arising from research at the dental school, University of Melbourne. Paul took an R&D project from the laboratory bench to a commercial product now marketed globally as an additive to oral care products. More recently Paul worked in a number of positions with Mesoblast Ltd. Paul was the inaugural COO and moved into Executive Vice President New Product Development for the adult stem cell company. Paul is the founder of Paradigm Biopharmaceuticals.
|
| Mr Amos Meltzer | Non-Executive Director | Dec 2020 |
Mr Meltzer has over 25 years of experience in international trade and in commercialising technologies, principally in the life sciences sector. He has presided over life science research and product development projects clinical trials as well as the commercialisation of life sciences assets through both licensing and the sale and marketing of a pharmaceutical product. Previously Amos served as General Counsel and IP director at two Nasdaq-listed companies Compugen and Gilat, as a non-executive director of a biotechnology company Evogene and as VP of Business Development and then CEO of biopharmaceutical company Immuron. Amos currently serves as Chief Legal Officer of neuro-medical device company Synchron, chairman of the Board of surgeons' education services company Vasculab and as a legal advisor to a number of ASX listed and private life science companies. Amos is member of the Risk Management Committee.
|
| Mr Matthew James Fry | Non-Executive Director | Mar 2024 |
Mr Fry joins the Paradigm board with more than 25 years in business creation, strategy, and expansion in healthcare and medical diagnostics globally. He is currently the CEO, Managing Director and Founder of AM Diagnostics Pty Ltd, a manufacturer and distributor of medical diagnostic products. Matthew has experience with global regulatory agencies, in particular the Australian TGA and US FDA. Through his role as Founder and CEO of AM Diagnostics, Matthew drove the company's expansion into the United States in 2009 and is a biotechnology device supplier with understanding of sales channels in the US medical wholesale market and retail market, and how to negotiate with private health providers.
|
| Ms Abby Macnish | Interim Company Secretary | Aug 2022 |
-
|
| Abby Macnish | Interim Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 16,098,954 | 4.59% |
| Citicorp Nominees Pty Limited | 15,194,109 | 4.34% |
| Sandhurst Trustees Ltd <Collins St Value Fund A/C> | 15,148,692 | 4.32% |
| Kzee Pty Ltd <Kzee Superannuation Fund A/C> | 11,380,902 | 3.25% |
| Mr Paul John Rennie | 8,500,548 | 2.43% |
| Netwealth Investments Limited <Wrap Services A/C> | 7,233,311 | 2.06% |
| BNP Paribas Noms Pty Ltd | 7,223,423 | 2.06% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 7,167,669 | 2.05% |
| Mr Evan Philip Clucas & Ms Leanne Jane Weston <Kuranga Nursery Super A/C> | 6,129,195 | 1.75% |
| Nancy Edith Wilson Ghosh <Ghosh Family A/C> | 3,475,835 | 0.99% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 2,470,966 | 0.71% |
| 39Kp Pty Ltd <Ross Family A/C> | 2,427,367 | 0.69% |
| Mr Adam William Huts | 2,405,000 | 0.69% |
| Wacc Pty Ltd <Progessive Global Fund A/C> | 2,337,318 | 0.67% |
| Mr Anthony Mark Van Der Steeg | 2,051,787 | 0.59% |
| Juzcorp Pty Limited <Gazal Holdings A/C> | 1,607,958 | 0.46% |
| Finclear Services Pty Ltd <Superhero Securities A/C> | 1,585,274 | 0.45% |
| Flinders Medical Centre Foundation | 1,562,000 | 0.45% |
| Ms Lenna Yu Ling Tye | 1,441,631 | 0.41% |
| Lempip Nominees Pty Ltd <Lempip Super Fund A/C> | 1,276,512 | 0.36% |
